Gilead Sciences Announces CEO John F. Milligan to Step Down
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer after a 28-year career with the company. Dr. Milligan will remain in his current position through the end of the year, while the Board of Directors conducts a search to identify a successor.
“It has been an honor to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the Board and I have agreed it is a good time to turn the reins over to a new leader,” said Dr. Milligan. “I’m looking forward to a well-deserved break and will then move on to new and different opportunities.”
“Today, Gilead has the right strategy in place to successfully execute on its mission of improving the lives of people with some of the world’s most serious diseases, led by a robust HIV franchise, an industry-leading cell therapy platform and a late-stage pipeline in NASH and inflammation,” commented John C. Martin, PhD, Chairman of the Board of Directors. “Moreover, we have the resources to continue investing in and expanding our strong R&D pipeline, which remains paramount to our success. We are excited about our growth potential, and intend to hire a CEO who will build on the foundation that John Milligan has put in place and execute on our ambitious goals for the future.”
“On behalf of the entire Board, I want to thank John Milligan for his countless contributions to Gilead over nearly 30 years, and commend him for operating throughout his career with the highest personal and professional integrity,” said John Cogan, PhD, Lead Independent Director, Gilead Sciences Board of Directors. “Given his longstanding dedication to Gilead, it is no surprise that John is committed to facilitating a seamless transition for all of our stakeholders, as we work to identify his successor.”
Dr. Milligan will also step down from the Gilead Board of Directors at the end of the year. Additionally, Dr. Martin has announced his intent to step down from the Board at the time a new CEO joins the company, having determined that this would be a natural transition point from his successive roles as CEO, Executive Chairman and Chairman.
The Company today also released its financial results for the second quarter 2018. As previously announced, at 5:00 p.m. Eastern Time, management will host a conference call to discuss financial results and provide a general business update.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180725005853/en/
Contact information
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Amy
Flood, 650-522-5643
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Manhattan Associates Unveils Agentic AI Innovation at Momentum 202522.5.2025 10:00:00 EEST | Press release
Kicking off Momentum 2025, Manhattan Associates Inc. (NASDAQ: MANH) today announced sweeping Agentic AI support within Manhattan Active® solutions that includes intelligent, autonomous digital agents to revolutionise supply chain commerce execution, optimisation, and user experiences. These out-of-the-box AI agents, powered by large language models (LLMs) and Manhattan’s cloud-native, all-microservice API architecture, will autonomously perform tasks, adapt to changing conditions, and dynamically orchestrate workflows. This breakthrough marks a generational leap from traditional chatbots and static workflow configurations to dynamic, intelligent, and situationally aware orchestration across the entire supply chain and commerce lifecycle. Among the first groundbreaking AI agents announced are the Intelligent Store Manager, Labor Optimizer Agent, Wave Inventory Research Agent, Contextual Data Assistant, and Virtual Configuration Consultant. These digital agents allow users to interact wi
Empowering Local Industry: SFI Health ™ EMEA Commits to South African Packing Operations22.5.2025 09:30:00 EEST | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce that the packing of its branded products in South Africa will be now fully managed locally leveraging local talent and facilities. The company is known for its clinically researched products in microbiome, cognition, and well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521282786/en/ This initiative enhances SFI Health South Africa’s ability to offer greater flexibility in pack sizes, ensuring a product portfolio that aligns more closely with the needs of South African consumers. By taking this step, the company aims to make its scientifically supported health solutions more accessible, without compromising on quality or efficacy. Simultaneously, this initiative will have a positive ripple effect on the local economy: all packaging materials will be sourced from South African suppliers, and the produc
Lenovo Group: Q4 and Full Year Financial Results 2024/2522.5.2025 07:21:00 EEST | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today announced Q4 and full year results for the fiscal year 2024/25, reporting significant increases in overall group revenue and profit. For the full year, revenue grew 21% year-on-year to US$69.1 billion, marking the Group’s second-highest annual revenue in its history. Net income was up 36% year-on-year to US$1.4 billion on a non-Hong Kong Financial Reporting Standards (non-HKFRS[1]) basis. The Group’s diversified growth engines continue to accelerate, with non-PC revenue mix up nearly five points year-on-year to 47%. All business groups were healthy and strong and met their strategic intent and financial goals, and all sales geographies gained double-digit revenue growth year-on-year, reflecting the strength of the Group’s diversified businesses and resilient global footprint. The results were not only driven by the Group’s focus on executing a clear strategy, but also its end-to-end integr
Mastercard and OCTO Join Forces to Promote Responsible Driving Through Loyalty Programs21.5.2025 19:10:00 EEST | Press release
Mastercard and OCTO, a global leader in advanced telematics solutions and data analytics services for the insurance and automotive sectors, today announce a collaboration aimed at redefining the interaction between insurance companies and customers by encouraging safer driving behaviors through an innovative loyalty program. The partnership involves the integration of Mastercard’s SessionM – a platform designed to support businesses in managing customer loyalty and engagement – with OCTO’s patented scoring models, which assess driving behavior using either physical devices (black boxes) or digital solutions (apps). This agreement has a dual objective: for drivers, it provides tangible benefits such as discounts on auto, home, and travel insurance, as well as other rewards, in exchange for safe and responsible driving. For insurance companies, it enhances customer engagement and loyalty, reduces portfolio risk, and helps control costs through a continuous and interactive relationship wi
Boomi Recognized as a Leader for the 11th Time in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service21.5.2025 18:30:00 EEST | Press release
Boomi™, the leader in AI-driven automation, today announced it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS), for the 11th consecutive time – the longest in the report’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521105444/en/ In our opinion, Boomi’s continued industry recognition reflects its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in AI agent management, API management, and data management to help enterprises connect everything with one platform and drive intelligent automation at scale. Key advancements include: Launch of Boomi Agentstudio for AI Agent Management: Boomi recently introduced the only full agent lifecycle management solution that allows organizations to simply design, govern, and orchestrate all AI agents at scale, helping unlock h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom